Research Scientist, Reagent and Consumable Product Development

Job Location
Chesterford Research park
Cambridge, UK
United Kingdom
Industry leading package

company equity, annual bonus scheme, 10% pension, 25 days annual leave, private medical care and more!

Job Description

This is a unique opportunity to join a talented team of scientists developing groundbreaking sequencing technologies that are transforming healthcare and basic research. You will join the dynamic, multidisciplinary, team that builds, optimizes and commercialises the core biochemistries that underpin Illumina Sequencing platforms. You will be responsible for developing high performance, robust and very well characterized products, assays and processes that meet the needs and expectations of a wide range of customers, including those using Illumina technologies for diagnostic applications. You should have prior experience of commercial product development. Experience of developing diagnostic assays and of working under Quality System regulations is also desirable.



Job duties include but are not limited to:


  • Participate in development projects for Illumina’s DNA sequencers, designing and testing new reagents and assays in an effort to improve sequencing accuracy & throughput, system robustness and costs.
  • Design experiments and analyze complex data sets. Interpret and present results demonstrating feasibility of new protocols.
  • Document plans, processes and results, in accordance with Illumina product development processes and appropriate quality system regulations.
  • Optimize and simplify complex assays to achieve commercial levels of stability and performance
  • Solve complex developmental challenges and troubleshoot technical issues with sequencing workflows
  • Presentation of results to colleagues.
  • Manage cross-functional team to efficiently move products through pipeline
  • Build strong working relationships across sites and functional areas


This is a rare opportunity to work with a team at that develops core products for Illumina’s NGS technology platform.  It would suit an experienced scientist who can clearly demonstrate the ability to develop robust assays for a fast paced product development function.  Candidates form disciplines/industries such as medical diagnostics and clinical detection would be encouraged to apply.



Education and Experience:


  • PhD in a molecular biology or Biochemistry related field.
  • Proven experience in commercial product development, preferably in the molecular diagnostics area.
  • Experience with development for regulated markets, design controls and working knowledge of ISO13485, ISO9001 and QSR guidelines desired.
  • Strong background in biochemistry and molecular biology methods with a sound understanding of assay development required.
  • Strong communication and writing skills required to clearly explain complex issues, report technical progress and document process, plans and results rigorously.
  • Able to work effectively under pressure to meet scheduled deadlines and handle multiple activities simultaneously.
  • Strong data analysis skills, with the ability to interpret and draw conclusions from large amounts of complex data.
  • Experience with transfer of new products and processes to manufacturing and/or QC desired.
  • Must be detail oriented and highly motivated to be a part of a fast paced, multidisciplinary and dynamic environment.
About Our Organization

About Illumina:

Headquartered in San Diego, California, Illumina (NASDAQ: ILMN), is a leading developer, manufacturer, and marketer of next generation life science tools and integrated systems for large-scale analysis of genetic variation and biological function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With the innovative advances in our sequencing technologies, we are rapidly impacting the clinical market in areas such as reproductive health and oncology. The expanding Illumina oncology portfolio of next- generation sequencing NGS and microarray technologies is revolutionizing cancer genomics research. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

A part of the proposed tax bill in the US could make tuition waivers taxable, Vox reports.

The New York Times reports that only a subset of STEM worker are in demand.

US News & World Report says students pursuing STEM degrees should consider what they are getting into.

New study finds bias against female lecturers among student course evaluations, the Economist reports.